This trial will compare the effects of two different treatments for hemolysis (red blood cell breakdown) in patients with PNH. One treatment is a combination of two drugs, pozelimab and cemdisiran, and the other is ravulizumab. The trial will last 24 weeks, and the primary outcome measure is the effect on transfusions of RBCs. Secondary outcome measures include fatigue, quality of life, safety and tolerability, and complement activation.
4 Primary · 33 Secondary · Reporting Duration: Between week 8 and week 26, inclusive
Experimental Treatment
148 Total Participants · 2 Treatment Groups
Primary Treatment: Pozelimab · No Placebo Group · Phase 3
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: